Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
Aparna Raj ParikhBryant H CheeL Jill TsaiThereasa A RichKristin S PriceSonia A PatelLi ZhangFaaiz IbrahimMikaela EsquivelEmily E Van SeventerJoy X JarnaginVictoria M RaymondCarlos U CorveraKenzo HiroseEric K NakakuraRyan B CorcoranKatherine Van LoonChloe E AtreyaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
In this cohort of oligometastatic CRC, detection of ctDNA pre- or post-procedure was associated with inferior outcomes even after accounting for prognostic clinicopathologic variables. This suggests ctDNA may enhance current risk stratification methods helping evaluate novel treatments and surveillance strategies toward improving patient outcomes.